Dr Heymach on Updated AEGEAN Data in Resectable NSCLC

John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, discusses updated outcomes from the phase 3 AEGEAN trial (NCT03800134), which examined perioperative durvalumab (Imfinzi) vs placebo for the treatment of patients with resectable non–small cell lung cancer.